Replies to post #89728 on Biotech Values

[DewDiligence]

VRUS IDIX:

so the answer is partnerships.

Not just any partnership, but specifically the Roche partnership in charge of the INFORM-n program that has captured investors’ attention as though it were the only industry-wide attempt at an all-oral HCV regimen. This is a classic case of market inefficiency, IMHO.